Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
24.66 USD | -0.48% | -4.64% | -16.31% |
10/05 | Morgan Stanley Adjusts Price Target on Mirum Pharmaceuticals to $53 From $57, Keeps Overweight Rating | MT |
08/05 | Transcript : Mirum Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024 |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.31% | 1.17B | |
+28.82% | 48.16B | |
-1.09% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+10.11% | 25.59B | |
-22.87% | 18.96B | |
+8.05% | 12.92B | |
+29.01% | 12.03B | |
-1.85% | 11.77B |
- Stock Market
- Equities
- MIRM Stock
- News Mirum Pharmaceuticals, Inc.
- Transcript : Mirum Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 10